N@N

Brian Skorney Maintained (VRTX) at Buy and Held Target at $240 on, Jan 30th, 2022

Brian Skorney of Baird, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $240 on, Jan 30th, 2022.

Brian has made no other calls on VRTX in the last 4 months.

There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 2 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022
• Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021

These are the ratings of the 7 analyists that currently disagree with Brian

---

• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
• Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
• Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $265 on, Wednesday, December 22nd, 2021
• Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
• Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $265 on, Thursday, December 2nd, 2021
• Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
• Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021

Contributing Sources

---